Addex Completes Turnaround, Prepares For Phase III Dyskinesia Study

 
• By John Davis

Geneva, Switzerland-based Addex Therapeutics has raised CHF40m to pursue its novel negative allosteric modulator in a late-stage study for levodopa-induced dyskinesia associated with Parkinson's disease.  

Cubes
Addex Completes Another Step In Its Business Development Strategy • Source: Shutterstock

More from Financing

More from Business